Register
Journal Updates
eMediNexus Coverage from: 
ASCO clinical practice guidelines for HER2-positive breast cancer
eMediNexus,  06 July 2018
remove_red_eye 698 Views
#Cardiology #Hematology #Oncology #Radiology

0 Read Comments                

The American Society of Clinical Oncology (ASCO) has updated its clinical practice guidelines on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer published online June 25, 2015 in the Journal of Clinical Oncology. As per the guideline, HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for patients with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now